^
    No biomarker
    HL
    brentuximab vedotin
    Sensitive
    :
    A1
    EHA 2021 - 4d
    No biomarker
    NHL
    rituximab + copanlisib
    Sensitive
    :
    B
    EHA 2021 - 4d
    TP53 mutation
    Small Lymphocytic Lymphoma
    LOXO-305
    Sensitive
    :
    C3
    EHA 2021 - 4d
    Chr del(17p)
    Small Lymphocytic Lymphoma
    LOXO-305
    Sensitive
    :
    C3
    EHA 2021 - 4d
    BCL2 expression + MYC expression
    Diffuse Large B Cell Lymphoma
    lenalidomide + zanubrutinib
    Sensitive
    :
    C3
    - 4d
    TP53 mutation
    Lymphoma
    T-lymphocyte cell therapy
    Sensitive
    :
    C3
    EHA 2021 - 4d
    TNFRSF8 negative
    Peripheral T-cell Lymphoma
    chidamide
    Sensitive
    :
    C3
    EHA 2021 - 4d
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    lenalidomide + zanubrutinib
    Sensitive
    :
    C3
    EHA 2021 - 4d
    No biomarker
    Small Lymphocytic Lymphoma
    zanubrutinib
    Sensitive
    :
    A1
    BeiGene Press Release - 2wk
    No biomarker
    Diffuse Large B Cell Lymphoma
    loncastuximab tesirine
    Sensitive
    :
    A1
    FDA - 3wk
    No biomarker
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Mediastinal B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Mantle Cell Lymphoma
    brexucabtagene autoleucel
    Sensitive
    :
    A1
    No biomarker
    NHL
    brentuximab vedotin
    Sensitive
    :
    A1
    ALK positive
    NHL
    crizotinib
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive
    :
    A1
    No biomarker
    Lymphoma
    axicabtagene ciloleucel
    Resistant
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Sensitive
    :
    A1
    CD20 positive
    Diffuse Large B Cell Lymphoma
    Rixathon (rituximab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Burkitt Lymphoma
    cyclophosphamide intravenous
    Sensitive
    :
    A1
    No biomarker
    Burkitt Lymphoma
    rituximab
    Sensitive
    :
    A1
    No biomarker
    Mantle Cell Lymphoma
    ICP-022
    Sensitive
    :
    A1
    No biomarker
    Small Lymphocytic Lymphoma
    ICP-022
    Sensitive
    :
    A1
    TNFRSF8 positive
    HL
    brentuximab vedotin
    Sensitive
    :
    A1
    No biomarker
    Mantle Cell Lymphoma
    lenalidomide
    Sensitive
    :
    A1
    CD20 expression
    NHL
    rituximab-arrx
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    rituximab + lenalidomide
    Sensitive
    :
    A1
    No biomarker
    HL
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    HL
    carmustine
    Sensitive
    :
    A1
    No biomarker
    NHL
    carmustine
    Sensitive
    :
    A1
    CD20 positive
    Diffuse Large B Cell Lymphoma
    Truxima (rituximab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    Truxima (rituximab biosimilar)
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES